Compounds and methods targeting interleukin-34
Novel anti-IL-34 antibodies with optimized CDRs and modified IgG4 Fc regions address the limitations of existing antibodies by enhancing binding and stability, effectively neutralizing IL-34 to reduce neuroinflammation and improve diagnostic accuracy in diseases like Alzheimer's disease.
Patent Information
- Application Number
- TW111141269
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-10-29
- Filing Date
- 2022-10-28
- Publication Date
- 2026-08-01
- Estimated Expiration
- 2042-10-27
AI Technical Summary
Current anti-IL-34 antibodies lack desirable binding and dissociation rates, efficacy in neutralizing human IL-34, sustained duration of action, limited induction of unwanted cytokine release, acceptable immunogenicity, and stability, making them unsuitable for effective treatment and diagnostic applications in neuroinflammatory diseases like Alzheimer's disease.
Development of novel anti-human IL-34 antibodies with specific CDR combinations and modified IgG4 Fc regions to enhance binding affinity, reduce effector function, and improve stability, solubility, and pharmacokinetic properties, allowing for effective neutralization of IL-34 and modulation of immune responses.
The novel antibodies demonstrate high specificity and affinity for IL-34, reducing neuroinflammation, providing sustained therapeutic effects and improved diagnostic sensitivity, while minimizing adverse immune responses and cytokine release.